Clinical Policy: Risperidone Long-Acting Injection (Perseris, Risperdal Consta)
Reference Number: CP.PHAR.293
Effective Date: 12.01.16
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Risperidone (Perseris™, Risperdal Consta®) is an atypical antipsychotic.

FDA Approved Indication(s)
Risperdal Consta is indicated:
- For the treatment of schizophrenia
- For the maintenance treatment of bipolar I disorder as monotherapy or as adjunctive therapy to lithium or valproate

Perseris is indicated for the treatment of schizophrenia in adults.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Perseris and Risperdal Consta are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Schizophrenia or Bipolar Disorder (must meet all):
      1. Diagnosis of schizophrenia or bipolar disorder;
      2. Prescribed by or in consultation with a psychiatrist;
      3. Age ≥ 18 years;
      4. Member meets one of the following (a or b):
         a. History of non-adherence to oral antipsychotic therapy (see Appendix D for examples) and has established tolerability to oral risperidone;
         b. Therapy was initiated in an inpatient setting during a recent (within 60 days) hospital admission;
      5. Request meets one of the following (a or b):
         a. For Perseris requests, dose does not exceed 120 mg every four weeks;
         b. For Risperdal Consta requests, dose does not exceed 50 mg every two weeks.

   Approval duration: 6 months

   B. Other diagnoses/indications
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is
II. Continued Therapy

A. Schizophrenia or Bipolar Disorder (must meet all):
   1. Currently receiving medication via Centene benefit, or documentation supports one of the following (a or b):
      a. Member is currently receiving the requested medication for a covered indication and has received this medication for at least 30 days;
      b. Therapy was initiated in an inpatient setting, for a covered indication, during a recent (within 60 days) hospital admission;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, request meets one of the following (a or b):
      a. For Perseris requests, new dose does not exceed 120 mg every four weeks;
      b. For Risperdal Consta requests, new dose does not exceed 50 mg every two weeks.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents;

B. Dementia-related psychosis.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>risperidone (Risperdal®)</td>
<td>Schizophrenia Adults: initially, 2 mg/day PO (as a single dose) or 1 mg PO BID; adjust as tolerated to</td>
<td>Schizophrenia: 16 mg/day Bipolar disorder: 6 mg/day</td>
</tr>
</tbody>
</table>
**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone (Risperdal Consta)</td>
<td>Bipolar disorder, Schizophrenia</td>
<td>25 mg IM every 2 weeks. Some patients not responding to 25 mg may benefit from a higher dose of 37.5 mg or 50 mg.</td>
<td>50 mg IM every 2 weeks</td>
</tr>
<tr>
<td>Risperidone (Perseris)</td>
<td>Schizophrenia</td>
<td>90 mg or 120 mg SC once monthly</td>
<td>120 mg every 4 weeks</td>
</tr>
</tbody>
</table>
VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone (Risperdal Consta)</td>
<td>Vial kits: 12.5 mg, 25 mg, 37.5 mg, and 50 mg</td>
</tr>
<tr>
<td>Risperidone (Perseris)</td>
<td>Extended-release injectable suspension: 90 mg, 120 mg</td>
</tr>
</tbody>
</table>

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.PHARM.122.LAI Antipsychotics and converted to new template. Age removed and max dose added. Hypersensitivity contraindication added per PI. Appendix B: Oral Antipsychotics – reviewed, edited and updated per UptoDate and FDA websites (5-7). Specialist review by psychiatrist.</td>
<td>11.16</td>
<td>12.16</td>
</tr>
<tr>
<td>Converted to new template. Added age restriction per PI. Removed requirements related to hypersensitivity to either risperidone or paliperidone and history of dementia-related psychosis per safety approach. Increased initial approval duration from 3 to 6 months. Re-auth: updated to allow continuation of therapy for schizophrenia and bipolar disorder. Added dementia-related psychosis under section III.</td>
<td>07.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: policies combined for Medicaid and HIM lines of business; Medicaid: removed requirement related to therapeutic plan since specialist is involved in care; HIM: removed “no history of dementia-related psychosis” as a requirement and added it to section III Diagnoses/Indications for which coverage is NOT authorized; extended initial approval duration from 3 to 6 months; references reviewed and updated.</td>
<td>05.04.18</td>
<td>08.18</td>
</tr>
<tr>
<td>Initial and continued therapy criteria are revised to allow approval of Risperdal Consta for members who initiate therapy during a recent inpatient visit, without the requirement to step through oral agents.</td>
<td>02.26.19</td>
<td>02.19</td>
</tr>
<tr>
<td>No significant changes; added Commercial line of business; added Perseris to policy per SDC and prior clinical guidance.</td>
<td>03.04.19</td>
<td></td>
</tr>
<tr>
<td>3Q 2019 annual review: no significant changes; added black box warnings; references reviewed and updated.</td>
<td>06.03.19</td>
<td>08.19</td>
</tr>
</tbody>
</table>
**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>3Q 2020 annual review: no significant changes; references reviewed and updated.</td>
<td>05.12.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>
This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.